Development of Novel Prime-Boost Strategies Based on a Tri-Gene Fusion Recombinant L. tarentolae Vaccine against Experimental Murine Visceral Leishmaniasis

PLoS Neglected Tropical Diseases

Volumn 7, Issue 4, 2013, Pages

  Saljoughian, Noushin ^a   Taheri, Tahereh ^a   Zahedifard, Farnaz ^a   Taslimi, Yasaman ^a   Doustdari, Fatemeh ^a   Bolhassani, Azam ^a   Doroud, Delaram ^a   Azizi, Hiva ^b   Heidari, Kazem ^c   Vasei, Mohammad ^d   Namvar Asl, Nabiollah ^a   Papadopoulou, Barbara ^b   Rafati, Sima ^a  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

^b LAVAL UNIVERSITY   (Canada)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 10; INTERLEUKIN 2; LEISHMANIA TARENTOLAE VACCINE; LEISHMANIA VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIFLUORESCENCE MICROSCOPY; FEMALE; FLOW CYTOMETRY; FUSION GENE; GENE CONSTRUCT; GENE EXPRESSION; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNIZATION; ION EXCHANGE CHROMATOGRAPHY; LEISHMANIA INFANTUM; MOUSE; NONHUMAN; PARASITE LOAD; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOUTHERN BLOTTING; VISCERAL LEISHMANIASIS; WESTERN BLOTTING;

EID: 84876864811     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0002174     Document Type: Article

References (85)

1. Wilson ME, (1993) Leishmaniasis. Curr Opin Infect Dis 6: 331-340.
2. Pearson R, Sousa A, (1996) Clinical spectrum of Leishmaniasis. Clin Infect Dis 22 (1) (): 1-13.
3. Desjeux P, (2004) Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 27: 305-318.
4. Herwaldt BL, (1999) Leishmaniasis. Lancet 354: 1191-1199.
5. Rioux JA, Lanotte G, Serres E, Pratlong F, Bastien P, et al. (1990) Taxonomy of Leishmania. Use of isoenzymes. Suggestions for a new classification. Ann Parasitol Hum Comp 65: 111-125.
6. Desjeux P, Alvar J, (2003) Leishmania/HIV co-infections: epidemiology in Europe. Ann Trop Med Parasitol 97: 3-15.
7. Sinha PK, Pandey K, Bhattacharya SK, (2005) Diagnosis & management of leishmania/HIV co-infection. Indian J Med Res 121: 407-414.
8. Organization WH (1998) Advances in battle against leishmaniasis. TDR News 1998 Oct (57) (): 2.
9. Murray HW, (2001) Clinical and experimental advances in treatment of visceral leishmaniasis. Antimicrob Agents Chemother 45: 2185-2197.
10. Sundar S, More D, Singh M, Singh V, Sharma S, et al. (2000) Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 31: 1104-1107.
11. Modabber F, (1995) Vaccines against leishmaniasis. Ann Trop Med Parasitol 89 Suppl 1: 83-88.
12. Handman E, (2001) Leishmaniasis: current status of vaccine development. Clin Microbiol Rev 14: 229-243.
13. Sukumaran B, Madhubala R, (2004) Leishmaniasis: current status of vaccine development. Curr Mol Med 4: 667-679.
14. Khamesipour A, Dowlati Y, Asilian A, Hashemi-Fesharki R, Javadi A, et al. (2005) Leishmanization: use of an old method for evaluation of candidate vaccines against leishmaniasis. Vaccine 23: 3642-3648.
15. Nadim A, Javadian E, Tahvildar-Bidruni G, Ghorbani M, (1983) Effectiveness of leishmanization in the control of cutaneous leishmaniasis. Bull Soc Pathol Exot Filiales 76: 377-383.
16. Evans KJ, Kedzierski L, (2012) Development of Vaccines against Visceral Leishmaniasis. J Trop Med 2012: 892817.
17. Coler RN, Reed SG, (2005) Second-generation vaccines against leishmaniasis. Trends Parasitol 21: 244-249.
18. Piedrafita D, Xu D, Hunter D, Harrison RA, Liew FY, (1999) Protective immune responses induced by vaccination with an expression genomic library of Leishmania major. J Immunol 163: 1467-1472.
19. Molano I, Alonso MG, Miron C, Redondo E, Requena JM, et al. (2003) A Leishmania infantum multi-component antigenic protein mixed with live BCG confers protection to dogs experimentally infected with L. infantum. Vet Immunol Immunopathol 92: 1-13.
20. Coler RN, Goto Y, Bogatzki L, Raman V, Reed SG, (2007) Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cells. Infect Immun 75: 4648-4654.
21. Gradoni L, Foglia Manzillo V, Pagano A, Piantedosi D, De Luna R, et al. (2005) Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals. Vaccine 23: 5245-5251.
22. Bertholet S, Goto Y, Carter L, Bhatia A, Howard RF, et al. (2009) Optimized subunit vaccine protects against experimental leishmaniasis. Vaccine 27: 7036-7045.
23. Chakravarty J, Kumar S, Trivedi S, Rai VK, Singh A, et al. (2011) A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis. Vaccine 29: 3531-3537.
24. Belkaid Y, Piccirillo CA, Mendez S, Shevach EM, Sacks DL, (2002) CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 420: 502-507.
25. Uzonna JE, Wei G, Yurkowski D, Bretscher P, (2001) Immune elimination of Leishmania major in mice: implications for immune memory, vaccination, and reactivation disease. J Immunol 167: 6967-6974.
26. Mitchell GF, Handman E, Spithill TW, (1984) Vaccination against cutaneous leishmaniasis in mice using nonpathogenic cloned promastigotes of Leishmania major and importance of route of injection. Aust J Exp Biol Med Sci 62 (Pt 2) (): 145-153.
27. Daneshvar H, Coombs GH, Hagan P, Phillips RS, (2003) Leishmania mexicana and Leishmania major: attenuation of wild-type parasites and vaccination with the attenuated lines. J Infect Dis 187: 1662-1668.
28. Gorczynski RM, (1985) Immunization of susceptible BALB/c mice against Leishmania braziliensis. II. Use of temperature-sensitive avirulent clones of parasite for vaccination purposes. Cell Immunol 94: 11-20.
29. Kimsey PB, Theodos CM, Mitchen TK, Turco SJ, Titus RG, (1993) An avirulent lipophosphoglycan-deficient Leishmania major clone induces CD4+ T cells which protect susceptible BALB/c mice against infection with virulent L. major. Infect Immun 61: 5205-5213.
30. Titus RG, Gueiros-Filho FJ, de Freitas LA, Beverley SM, (1995) Development of a safe live Leishmania vaccine line by gene replacement. Proc Natl Acad Sci U S A 92: 10267-10271.
31. Alexander J, Coombs GH, Mottram JC, (1998) Leishmania mexicana cysteine proteinase-deficient mutants have attenuated virulence for mice and potentiate a Th1 response. J Immunol 161: 6794-6801.
32. Hubel A, Krobitsch S, Horauf A, Clos J, (1997) Leishmania major Hsp100 is required chiefly in the mammalian stage of the parasite. Mol Cell Biol 17: 5987-5995.
33. Silvestre R, Cordeiro-Da-Silva A, Santarem N, Vergnes B, Sereno D, et al. (2007) SIR2-deficient Leishmania infantum induces a defined IFN-gamma/IL-10 pattern that correlates with protection. J Immunol 179: 3161-3170.
34. Uzonna JE, Spath GF, Beverley SM, Scott P, (2004) Vaccination with phosphoglycan-deficient Leishmania major protects highly susceptible mice from virulent challenge without inducing a strong Th1 response. J Immunol 172: 3793-3797.
35. Papadopoulou B, Roy G, Breton M, Kundig C, Dumas C, et al. (2002) Reduced infectivity of a Leishmania donovani biopterin transporter genetic mutant and its use as an attenuated strain for vaccination. Infect Immun 70: 62-68.
36. Dumas C, Ouellette M, Tovar J, Cunningham ML, Fairlamb AH, et al. (1997) Disruption of the trypanothione reductase gene of Leishmania decreases its ability to survive oxidative stress in macrophages. EMBO J 16: 2590-2598.
37. Raymond F, Boisvert S, Roy G, Ritt JF, Legare D, et al. (2012) Genome sequencing of the lizard parasite Leishmania tarentolae reveals loss of genes associated to the intracellular stage of human pathogenic species. Nucleic Acids Res 40: 1131-1147.
38. Breton M, Tremblay MJ, Ouellette M, Papadopoulou B, (2005) Live nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis. Infect Immun 73: 6372-6382.
39. Wilson V, Southgate B, (1978) Lizard leishmania. Biology of the Kinetoplastida. San Diego, CA: Academic Press pp. 244-268.
40. Charest H, Matlashewski G, (1994) Developmental gene expression in Leishmania donovani: differential cloning and analysis of an amastigote-stage-specific gene. Mol Cell Biol 14: 2975-2984.
41. Azizi H, Hassani K, Taslimi Y, Najafabadi HS, Papadopoulou B, et al. (2009) Searching for virulence factors in the non-pathogenic parasite to humans Leishmania tarentolae. Parasitology 136: 723-735.
42. Mizbani A, Taheri T, Zahedifard F, Taslimi Y, Azizi H, et al. (2009) Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis. Vaccine 28: 53-62.
43. Rafati S, Salmanian AH, Hashemi K, Schaff C, Belli S, et al. (2001) Identification of Leishmania major cysteine proteinases as targets of the immune response in humans. Mol Biochem Parasitol 113: 35-43.
44. Rafati S, Nakhaee A, Taheri T, Ghashghaii A, Salmanian AH, et al. (2003) Expression of cysteine proteinase type I and II of Leishmania infantum and their recognition by sera during canine and human visceral leishmaniasis. Exp Parasitol 103: 143-151.
45. Coombs GH, Mottram JC (1997) Proteinases of trypanosomes and Leishmania: biology and control. London, UK: Oxford CAB International. pp. 177-179.
46. Robertson CD, Coombs GH, North MJ, Mottram JC, (1996) Parasite cysteine proteinases. Perspectives in Drug Discovery and Design. ESCOM Science Publisher 6: 99.
47. Mottram JC, North MJ, Barry JD, Coombs GH, (1989) A cysteine proteinase cDNA from Trypanosoma brucei predicts an enzyme with an unusual C-terminal extension. FEBS Letters 258: 211-215.
48. Huete-Perez J, Engel J, Brinen L, Mottram JC, McKerrow J, (1999) Protease trafficking in two primitive eukaryotes is mediated by a prodomain protein motif. Journal of Biological Chemistry 274: 16249-16256.
49. Rafati S, Zahedifard F, Azari MK, Taslimi Y, Taheri T, (2008) Leishmania infantum: prime boost vaccination with C-terminal extension of cysteine proteinase type I displays both type 1 and 2 immune signatures in BALB/c mice. Exp Parasitol 118: 393-401.
50. Rafati S, Nakhaee A, Taheri T, Taslimi Y, Darabi H, et al. (2005) Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum. Vaccine 23: 3716-3725.
51. Rafati S, Zahedifard F, Nazgouee F, (2006) Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis. Vaccine 24: 2169-2175.
52. Rafati S, Salmanian AH, Taheri T, Vafa M, Fasel N, (2001) A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major. Vaccine 19: 3369-3375.
53. Zadeh-Vakili A, Taheri T, Taslimi Y, Doustdari F, Salmanian AH, et al. (2004) Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis. Vaccine 22: 1930-1940.
54. Doroud D, Zahedifard F, Vatanara A, Taslimi Y, Vahabpour R, et al. (2011) C-terminal domain deletion enhances the protective activity of cpa/cpb loaded solid lipid nanoparticles against Leishmania major in BALB/c mice. PLoS Negl Trop Dis 5: e1236.
55. Greenland JR, Letvin NL, (2007) Chemical adjuvants for plasmid DNA vaccines. Vaccine 25: 3731-3741.
56. Doroud D, Vatanara A, Zahedifard F, Gholami E, Vahabpour R, et al. (2010) Cationic solid lipid nanoparticles loaded by cysteine proteinase genes as a novel anti-leishmaniasis DNA vaccine delivery system: characterization and in vitro evaluations. J Pharm Pharm Sci 13: 320-335.
57. Papadopoulou B, Roy G, Ouellette M, (1992) A novel antifolate resistance gene on the amplified H circle of Leishmania. EMBO J 11: 3601-3608.
58. Sambrook J, Fritsch E, Maniatis T (1989) Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Press.
59. Doroud D, Zahedifard F, Vatanara A, Najafabadi AR, Taslimi Y, et al. (2011) Delivery of a cocktail DNA vaccine encoding cysteine proteinases type I, II and III with solid lipid nanoparticles potentiate protective immunity against Leishmania major infection. J Control Release 153: 154-162.
60. Viana da Costa A, Huerre M, Delacre M, Auriault C, Correia Costa JM, et al. (2002) IL-10 leads to a higher parasite persistence in a resistant mouse model of Leishmania major infection. Parasitol Int 51: 367-379.
61. Buffet PA, Sulahian A, Garin YJ, Nassar N, Derouin F, (1995) Culture microtitration: a sensitive method for quantifying Leishmania infantum in tissues of infected mice. Antimicrob Agents Chemother 39: 2167-2168.
62. Lachaud L, Marchergui-Hammami S, Chabbert E, Dereure J, Dedet JP, et al. (2002) Comparison of Six PCR Methods Using Peripheral Blood for Detection of Canine Visceral Leishmaniasis. Journal of Clinical Microbiology 40: 210-215.
63. Carrion J, Nieto A, Iborra S, Iniesta V, Soto M, et al. (2006) Immunohistological features of visceral leishmaniasis in BALB/c mice. Parasite Immunol 28: 173-183.
64. Alexander J, McFarlane E, (2008) Can type-1 responses against intracellular pathogens be T helper 2 cytokine dependent? Microbes Infect 10: 953-959.
65. Modabber F, (2010) Leishmaniasis vaccines: past, present and future. Int J Antimicrob Agents 36 Suppl 1: S58-61.
66. Kaye PM, Curry AJ, Blackwell JM, (1991) Differential production of Th1- and Th2-derived cytokines does not determine the genetically controlled or vaccine-induced rate of cure in murine visceral leishmaniasis. J Immunol 146: 2763-2770.
67. Alexander J, Bryson K, (2005) T helper (h)1/Th2 and Leishmania: paradox rather than paradigm. Immunol Lett 99: 17-23.
68. Wilson ME, Jeronimo SM, Pearson RD, (2005) Immunopathogenesis of infection with the visceralizing Leishmania species. Microb Pathog 38: 147-160.
69. Rodrigues OR, Marques C, Soares-Clemente M, Ferronha MH, Santos-Gomes GM, (2009) Identification of regulatory T cells during experimental Leishmania infantum infection. Immunobiology 214: 101-111.
70. Handman E, (1997) Leishmania vaccines: old and new. Parasitol Today 13: 236-238.
71. Handman E, (2001) Protective saliva: a novel approach to a Leishmania vaccine. Trends Parasitol 17: 513-514.
72. Streit JA, Recker TJ, Filho FG, Beverley SM, Wilson ME, (2001) Protective immunity against the protozoan Leishmania chagasi is induced by subclinical cutaneous infection with virulent but not avirulent organisms. J Immunol 166: 1921-1929.
73. Zhang WW, Matlashewski G, (2001) Characterization of the A2-A2rel gene cluster in Leishmania donovani: involvement of A2 in visceralization during infection. Mol Microbiol 39: 935-948.
74. Selvapandiyan A, Debrabant A, Duncan R, Muller J, Salotra P, et al. (2004) Centrin gene disruption impairs stage-specific basal body duplication and cell cycle progression in Leishmania. J Biol Chem 279: 25703-25710.
75. Nylen S, Maurya R, Eidsmo L, Manandhar KD, Sundar S, et al. (2007) Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3) regulatory T cells in human visceral leishmaniasis. J Exp Med 204: 805-817.
76. Gerosa F, Paganin C, Peritt D, Paiola F, Scupoli MT, et al. (1996) Interleukin-12 primes human CD4 and CD8 T cell clones for high production of both interferon-gamma and interleukin-10. J Exp Med 183: 2559-2569.
77. O'Garra A, Vieira PL, Vieira P, Goldfeld AE, (2004) IL-10-producing and naturally occurring CD4+ Tregs: limiting collateral damage. J Clin Invest 114: 1372-1378.
78. Murray HW, Delph-Etienne S, (2000) Roles of endogenous gamma interferon and macrophage microbicidal mechanisms in host response to chemotherapy in experimental visceral leishmaniasis. Infect Immun 68: 288-293.
79. Haldar JP, Ghose S, Saha KC, Ghose AC, (1983) Cell-mediated immune response in Indian kala-azar and post-kala-azar dermal leishmaniasis. Infect Immun 42: 702-707.
80. Nieto A, Domínguez-Bernal G, Orden JA, Fuente RDL, Madrid-Elena N, et al. (2011) Mechanisms of resistance and susceptibility to experimental visceral leishmaniosis: BALB/c mouse versus syrian hamster model. Veterinary Research 42: 39.
81. Stanley AC, Engwerda CR, (2007) Balancing immunity and pathology in visceral leishmaniasis. Immunol Cell Biol 85: 138-147.
82. Bankoti R, Stager S, (2012) Differential Regulation of the Immune Response in the Spleen and Liver of Mice Infected with Leishmania donovani. J Trop Med 2012: 639304.
83. Rolao N, Cortes S, Gomes-Pereira S, Campino L, (2007) Leishmania infantum: mixed T-helper-1/T-helper-2 immune response in experimentally infected BALB/c mice. Exp Parasitol 115: 270-276.
84. Murray HW, Squires KE, Miralles CD, Stoeckle MY, Granger AM, et al. (1992) Acquired resistance and granuloma formation in experimental visceral leishmaniasis. Differential T cell and lymphokine roles in initial versus established immunity. J Immunol 148: 1858-1863.
85. Stager S, Alexander J, Carter KC, Brombacher F, Kaye PM, (2003) Both interleukin-4 (IL-4) and IL-4 receptor alpha signaling contribute to the development of hepatic granulomas with optimal antileishmanial activity. Infect Immun 71: 4804-4807.